by David Wallace
For years, the medical community has told us the same thing when we’re diagnosed with early-stage myeloproliferative neoplasms: “Let’s watch and wait.” The thinking was straightforward: why expose someone to treatment side effects when they’re not yet symptomatic? But a study published this December in the journal Cancers is challenging that entire philosophy, especially when it comes to prefibrotic myelofibrosis.
The data shows that interferon treatment for myelofibrosis isn’t just about managing symptoms. It can actually modify the disease itself, potentially stopping progression before the bone marrow sustains permanent damage. That changes everything for patients facing these treatment decisions.
Why Prefibrotic Myelofibrosis Has Been a Gray Zone
Prefibrotic primary myelofibrosis (pre-PMF) has always occupied an uncomfortable middle ground. It’s not essential thrombocythemia, though patients often have high platelet counts as ET patients do. And it’s not yet overt primary myelofibrosis, though that’s exactly where it’s headed if there’s no intervention.
The problem is that these patients don’t feel sick. They don’t have the bone pain, the fatigue, or the massive spleens seen in advanced myelofibrosis. So historically, doctors have hesitated to treat them, worrying about side effects and overtreatment.
But here’s what the research now shows: while doctors watch and wait, the disease is quietly advancing. The bone marrow is slowly scarring. And once that fibrosis sets in, it’s typically irreversible.
Sigrid Machherndl-Spandl and her team’s study suggests a need for a paradigm shift. Early myelofibrosis treatment approaches can prevent irreversible damage before it occurs. If you’ve been told to “watch and wait” and you have concerns about this approach, this research gives you solid evidence to bring to your next appointment. It’s worth having an honest conversation with your hematologist about whether early treatment might be right for your specific situation.
Interferon Works Fast on Blood Counts
The researchers monitored 55 patients with precisely defined pre-PMF who received pegylated interferon treatment. The first noteworthy finding was the speed of response.
Within just three months of starting therapy, half of the patients achieved what’s called a complete hematological response, meaning their blood counts normalized. In two years, that number jumped to over 80%.
This statistic matters tremendously. High platelet counts and elevated white blood cells drive blood clots, which remain the number one cause of serious complications in MPN patients. When we talk about interferon therapy for myelofibrosis reducing thrombotic risk, we’re talking about preventing strokes, heart attacks, and pulmonary embolisms. The fact that interferon works this quickly means patients aren’t waiting months or years for protection.
The Real Prize: Stopping the Scarring
Controlling blood counts is important, but what patients really need is to change the course of the disease itself. In myelofibrosis, the enemy is fibrosis: the scarring of bone marrow that eventually leads to bone marrow failure.
This is where the 2025 data gets exciting. Among patients who had follow-up bone marrow biopsies, 73% either stayed stable or actually improved. More than 60% showed no progression of fibrosis, and about 12% saw their fibrosis grade go down.
Think about what that means. This isn’t just buying time. There’s potential to halt the progression of the scarring process.
How? Interferon appears to dial down the inflammatory signals, cytokines like TGF-beta, that drive the scarring process. By treating in the pre-fibrotic stage, there’s a window where it’s actually possible to prevent the irreversible changes that define late-stage disease. This is significant because the standard myelofibrosis life expectancy is typically 5 to 7 years from diagnosis, but early intervention may fundamentally alter that trajectory.
Not All Mutations Respond the Same Way
This is where the future of personalized treatment truly begins to unfold. Myeloproliferative neoplasms are driven by mutations in one of three genes: JAK2, CALR, or MPL. And it turns out, these mutations don’t all respond to interferon the same way.
JAK2-mutated patients did remarkably well. Nearly three-quarters achieved at least a 25% reduction in their cancer clone, and more than half saw their mutant cells drop by 50% or more. These are deep, meaningful responses.
CALR-mutated patients, on the other hand, had a much tougher time. Only about one in four achieved even a modest molecular response, and fewer than one in ten hit that deeper 50% threshold.
This split tells us something fundamental about how interferon works. The JAK2 mutation seems to make cancer cells more vulnerable to interferon through a mechanism involving the JAK1/STAT1 pathway. Interferon treatment for myelofibrosis may be most effective when the cancer cells are already connected to the pathway that the drug targets.
For CALR patients, different strategies might be needed: higher doses, longer treatment, or combination therapies. The point is, the same treatment approach doesn’t work for everyone.
What This Means for Patient Care
This study should change how doctors and patients approach prefibrotic myelofibrosis. The data make “watch and wait” harder to justify, particularly for those with JAK2 mutations.
The evidence now shows that early treatment for myelofibrosis with pegylated interferon can:
- Rapidly reduce thrombotic risk by normalizing blood counts
- Prevent or slow bone marrow scarring
- Reduce the burden of malignant cells, especially in JAK2-mutated disease
But treatment approaches also need to be smarter about who gets treated and how. A JAK2 patient and a CALR patient probably shouldn’t receive identical treatment plans. Genotype-specific approaches are needed.
For CALR patients specifically, the question becomes: do higher interferon doses help, or are combinations with other agents needed? These are the questions the field needs to answer next.
The Bottom Line
The evidence is mounting that early intervention with interferon in pre-fibrotic myelofibrosis can alter the natural history of this disease. This isn’t just about managing symptoms; there’s real potential to prevent the progression to overt myelofibrosis altogether.
For patients newly diagnosed with pre-PMF, especially those carrying a JAK2 mutation, the conversation about treatment should start now, not later. The window for disease modification exists in the early stages, before the bone marrow is permanently scarred.
This represents a meaningful shift in how the medical community thinks about these diseases, moving from reactive medicine to proactive medicine. Based on what we’re seeing in the data, that’s precisely where we should be. As patients, we need to be informed advocates for ourselves, asking the challenging questions about whether “watch and wait” is truly the best approach for our individual situations.
Frequently Asked Questions
What is interferon, and how does it work for myelofibrosis?
Interferon is a naturally occurring protein that helps regulate the immune system. In myelofibrosis treatment, pegylated interferon (a long-acting form) works by reducing the production of abnormal blood cells and dampening the inflammatory signals that cause bone marrow scarring. The 2025 study shows it can normalize blood counts within three months and prevent disease progression when used early.
When should treatment for myelofibrosis begin?
Traditional practice has favored “watch and wait” until symptoms develop. However, recent evidence suggests that early treatment in pre-fibrotic myelofibrosis, especially for patients with JAK2 mutations, can prevent irreversible bone marrow damage. The key is intervening before significant fibrosis develops. If you have any doubts about the “watch and wait” approach, discuss this research with your hematologist and ask whether early treatment might be appropriate for your specific situation.
Does my genetic mutation affect how well interferon will work?
Yes, significantly. Patients with JAK2 mutations respond much better to interferon therapy, with over 70% achieving meaningful reductions in their cancer cells. CALR-mutated patients show more modest responses, with only about 25% achieving similar results. This difference is important for treatment planning and setting realistic expectations.
What are the benefits of early myelofibrosis treatment?
Early treatment with pegylated interferon offers three major benefits: it rapidly reduces the risk of blood clots by normalizing blood counts, it prevents or slows bone marrow scarring (fibrosis), and it reduces the burden of malignant cells in the bone marrow. These effects can potentially stop the disease from progressing to advanced myelofibrosis.
How long does it take for interferon to work in myelofibrosis?
Interferon works relatively quickly. In the 2025 study, 50% of patients achieved normal blood counts within three months of starting therapy. By 24 months, over 80% had achieved this response. Molecular responses (reduction in cancer cells) take longer but become more pronounced over time.
What’s the difference between prefibrotic and overt myelofibrosis?
Pre-fibrotic myelofibrosis is an early stage where patients have abnormal blood counts but minimal bone marrow scarring and few symptoms. Overt myelofibrosis involves significant bone marrow scarring, leading to bone marrow failure, severe symptoms like fatigue and enlarged spleen, and a much worse prognosis. The goal of early treatment is to prevent progression from the prefibrotic to the overt stage.
Is interferon better than JAK inhibitors for myelofibrosis?
They serve different purposes. JAK inhibitors like ruxolitinib are excellent for managing symptoms in advanced myelofibrosis but don’t modify the underlying disease. Interferon, particularly when used early, appears to be a true disease modifier that can reduce the cancer burden and prevent progression. For early-stage, pre-fibrotic disease, interferon may be the better choice, especially in JAK2-mutated patients. The key difference is timing: JAK inhibitors work well for symptom control in later stages, while interferon shows the most promise when started before significant bone marrow damage occurs.
What are the side effects of interferon treatment?
Common side effects include flu-like symptoms (especially early in treatment), fatigue, mood changes, and low blood counts. These side effects are why doctors historically hesitated to use interferon in asymptomatic patients. However, modern pegylated formulations are better tolerated, and many patients adapt to the medication over time. The key is weighing these manageable side effects against the risk of disease progression.
Can interferon cure myelofibrosis?
While interferon isn’t considered a cure, it can induce long-lasting remissions and potentially prevent progression to advanced disease when used early. Some patients achieve deep molecular responses where the cancer cells become nearly undetectable. The earlier treatment begins (in the prefibrotic stage), the better the chance of achieving durable disease control. In some cases, early interferon treatment may stabilize or even reverse early bone marrow changes, though this outcome varies by patient and requires close monitoring with bone marrow biopsies.
How do I know if early treatment is right for me?
This depends on several factors: your genetic mutation (JAK2 patients respond best), your risk category, your blood counts, and the degree of bone marrow changes on biopsy. The most important step is having a detailed discussion with a hematologist who specializes in myeloproliferative neoplasms. Bring up the recent data on early interferon use and ask whether it applies to your specific situation. Don’t hesitate to question the “watch and wait” approach if you have concerns, you have the right to understand all your treatment options.
What interferon medications are used for myelofibrosis?
The two main pegylated interferons used in clinical practice and research are Besremi (ropeginterferon alfa-2b) and Pegasys (peginterferon alfa-2a). While neither is currently FDA-approved specifically for myelofibrosis, both are used off-label based on growing clinical evidence. Besremi is FDA-approved for polycythemia vera and requires less frequent dosing (every two weeks), while Pegasys requires weekly injections. The choice between them often depends on individual patient factors, insurance coverage, and physician experience. These pegylated interferon formulations are generally better tolerated than older interferon preparations.
Where can I find more information about myelofibrosis?
- MPN Research Foundation – Myelofibrosis – A comprehensive nonprofit focused on research, education, and support for MPN patients, including MF.
- Blood Cancer United – Myelofibrosis – Patient support, disease facts, treatment options, and clinical trial info.
- Mayo Clinic – Myelofibrosis – Easy-to-understand disease overview, symptoms, diagnosis, treatments, and prognosis.
- MPN Cancer Connection – A nonprofit organization whose resource page features excellent information, including A Guide to Myelofibrosis, MF Treatment Options and Discussion Guide and How to Choose Your MPN Specialist: A Resource Guide for Patients
- Merk Manual (Consumer Edition)
- ClinicalTrials.gov – Myelofibrosis Trials – Clinical trials for MF therapies, including interferons and new agents.
Medical Disclaimer
This article is provided for educational and informational purposes only and is not intended as medical advice. It does not replace consultation with a qualified healthcare professional. Diagnosis, treatment decisions, and care plans should always be made in consultation with your physician or an appropriate MPN specialist who is familiar with your individual medical history.
* This research was compiled with the assistance of AI and reviewed/edited by David Wallace, MPN Patient Advocate
Reference:
Machherndl-Spandl S, Kiehberger M, Sygulla V, Kaynak E, Zach O, Webersinke G, Gruber-Rossipal C, Beham-Schmid C, Maier E, Strassl I, Clausen J, Nikoloudis A, Schimetta W, Rumpold H, Buxhofer-Ausch V.
Pegylated Interferon Alpha in Pre-Fibrotic Primary Myelofibrosis: A Retrospective Multicenter Study.
Cancers (Basel). 2025;17(24):3940.
https://www.mdpi.com/2072-6694/17/24/3940
Image Credit: AI Generated
